Chris Boshoff: Pfizer Continues to Lead in Antibody-Drug Conjugate Innovation
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“Proud to share that 25 years ago, Pfizer received approval for the first-ever antibody-drug conjugate (ADC) for a common leukemia. Today, thanks to the commitment of independent investigators, our medicine remains an important treatment option.
ADCs have since emerged as a powerful tool in the fight against cancer, with significant advances in antibody engineering, chemical synthesis and cancer biology helping to further our understanding of this technology and harness its potential to improve patient outcomes. Pfizer is continuing to lead in this potentially practice-changing science, with nearly half of all currently approved ADCs coming from Pfizer or using our technology.
Learn more about how we’re using our deep technical expertise to accelerate the next generation of ADCs with novel targets, along with other modalities to address cancer from multiple angles.”
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023